MarketPeel
Insider Trading Intelligence
Pricing
…
JS

John W. Smither

NAMS
DIRECTOR · NEWAMSTERDAM PHARMA CO N.V. · CIK 0001559583
FILING MIX · LIFETIME55%/45%
BUYS
31
SELLS
25
TOTAL VALUE
$727.4K
COMPANIES
3
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
101,763
AVG SELL PX
$21.09
TRADE KIND
SHOWING 56 / 56
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
16 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by John W. Smither, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d16+56.25%-3.35%+1.21%-4.56%-3.64%—
14d16+56.25%-3.13%+1.84%-4.97%-9.14%—
30d16+75.00%-12.04%+2.34%-14.39%-11.52%—
60d16+50.00%-8.65%+6.02%-14.67%-23.24%—
90d16+75.00%-11.05%+8.97%-20.02%-20.10%—
180d16+87.50%-24.91%+16.05%-40.96%-43.00%—
1y16+87.50%-45.01%+20.59%-65.60%-66.51%—
2y16+100.00%-44.64%+11.51%-63.60%-59.13%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NAMS · 10,360 shares · as of Jan 7, 2026
08,12516,25024,37532,500202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 31 buys / 25 sellsCOVERAGE · 27 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GNLX
GENELUX CORP
SALE
12,000$2.91$34.9K91,403Jul 1, 2026Jul 2, 2026 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
28,409——103,403Jun 16, 2026Jun 18, 2026 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
31,566——31,566Jun 16, 2026Jun 18, 2026 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASEGRANT
Stock grant
15,300——15,300Jan 7, 2026Jan 9, 2026 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASEGRANT
Stock grant
3,400——10,360Jan 7, 2026Jan 9, 2026 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
28,576——28,576Aug 27, 2025Aug 29, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
22,283——74,994Aug 27, 2025Aug 29, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASEGRANT
Stock grant
6,960——6,960Jan 7, 2025Jan 8, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASEGRANT
Stock grant
32,500——32,500Jan 6, 2025Jan 8, 2025 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
50,469——50,469Aug 1, 2024Dec 31, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
39,541——52,711Aug 1, 2024Aug 5, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
50,469——50,469Aug 1, 2024Aug 5, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASE
6,250——6,250May 29, 2024Jun 7, 2024 ↗View →
GNLX
GENELUX CORP
PURCHASE
6,250——13,170May 29, 2024Jun 7, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,793——2,793Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
8,379——0Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,572——11,365Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
25,718——0Feb 13, 2024Feb 15, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
PURCHASEGRANT
Stock grant
10,000——10,000Jan 1, 2024Jan 3, 2024 ↗View →
GNLX
GENELUX CORP
SALE
900$20.78$18.7K6,920Sep 13, 2023Sep 14, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
8,447——8,447Sep 11, 2023Sep 13, 2023 ↗View →
GNLX
GENELUX CORP
PURCHASEGRANT
Stock grant
6,920——7,820Sep 11, 2023Sep 13, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000Aug 31, 2023Sep 5, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,250$32.90$41.1K86,715Mar 10, 2021Mar 11, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
500$32.90$16.4K46,321Mar 10, 2021Mar 11, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
500$1.68$84046,821Mar 10, 2021Mar 11, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
500——44,982Mar 10, 2021Mar 11, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
12,396——97,684Mar 4, 2021Mar 5, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
12,396$1.68$20.8K46,321Mar 4, 2021Mar 5, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,500——33,925Mar 3, 2021Mar 5, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,800——28,800Mar 3, 2021Mar 5, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
773$34.20$26.4K24,425Mar 1, 2021Mar 3, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
750$1.68$1.3K25,948Feb 10, 2021Feb 12, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
750——45,482Feb 10, 2021Feb 12, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
2,000$35.64$71.3K87,965Feb 10, 2021Feb 12, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
750$35.64$26.7K25,198Feb 10, 2021Feb 12, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,250$35.00$43.8K25,198Feb 1, 2021Feb 3, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
3,750$35.00$131.3K89,965Feb 1, 2021Feb 3, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,250$1.68$2.1K26,448Feb 1, 2021Feb 3, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,250——46,232Feb 1, 2021Feb 3, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
500$1.68$84025,698Jan 19, 2021Jan 21, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
500$30.00$15.0K25,198Jan 19, 2021Jan 21, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,250$30.00$37.5K93,715Jan 19, 2021Jan 21, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
500——47,482Jan 19, 2021Jan 21, 2021 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
3,750$30.00$112.5K94,965Dec 14, 2020Dec 16, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,500$1.68$2.5K26,698Dec 14, 2020Dec 16, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,500$30.00$45.0K25,198Dec 14, 2020Dec 16, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,500——47,982Dec 14, 2020Dec 16, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
1,250$30.00$37.5K98,715Sep 29, 2020Oct 1, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
500$1.68$84024,375Sep 29, 2020Oct 1, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
500$30.00$15.0K23,875Sep 29, 2020Oct 1, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
500——49,482Sep 29, 2020Oct 1, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
Chief Financial Officer
14,875——110,080Jun 11, 2020Jun 15, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
14,875$1.68$25.0K123,840Jun 11, 2020Jun 15, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
12,000——12,000Feb 27, 2020Mar 3, 2020 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,000——108,965Feb 27, 2020Mar 3, 2020 ↗View →
Other insiders · NAMS
Loading peer insiders…
About this filer
CIK 0001559583
ROLE
Director
PRIMARY
NAMS
COMPANIES
3
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001559583DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback